Crunching the numbers. Responsibly.
BACKGROUND: To understand the impact and burden of disease experienced by patients with hereditary angioedema (HAE). OBJECTIVE: To determine whether the use of short message service (SMS) to communicate with patients with HAE facilitates the collection of attack rate, medication use, and quality of life measurements. METHODS: Patients aged 12 years and older with doctor-confirmed HAE C1-inhibitor deficiency types I and II were invited to participate. We devised a novel method for monitoring attacks by using questions weekly via SMS to gain a more accurate picture of the burden of HAE in Australian patients in real time. RESULTS: A total of 2,648 weekly SMS messages were sent to 47 participants; 1,892 responses were received (71%). Participants reported 463 attacks across all treatment groups. Sixty percent of attacks were treated. Icatibant and C1-inhibitor concentrate were administered IV for 210 and 67 attacks, respectively. Of the 463 recorded attacks, 23 necessitated presentation to the hospital (5%), predominantly for facial and/or throat swelling. Several participants reported attacks (n = 186), which they chose not to treat. Most of those attacks were rated mildly severe. Twenty-one participants reported lost days owing to HAE attacks (44.7%). Fifty-eight attacks (17%) resulted in time away from work or school, equating to a total of 85.5 days lost. CONCLUSIONS: This study was a first of its kind, real-world, prospective, observational study of Australian patients living with HAE. Despite the availability of effective on-demand therapies, HAE remains burdensome. Wider access to safe and effective prophylactic therapies is needed for patients living with HAE.
Despite the availability of effective on-demand therapies, HAE remains burdensome.
prospective attack, emergency-presentation, and productivity data support burden, although the small cohort and minor reporting discrepancies limit certainty
This study demonstrates that using modern prophylactic therapy for hereditary angioedema results in a reduction in attack rates.
causal framing is not identified by the small observational comparison with severe confounding by indication
The subcutaneous prophylactic use of C1-inhibitor concentrate may be beneficial in reducing ongoing attacks and preventing emergency admissions with prolonged hospitalizations.
the uncontrolled observational design cannot establish prevention of admissions, and hospital presentations were not lower in the prophylaxis group
Derived from the full evaluation — not a separate score.
Strengths
Weekly SMS questions with telephone follow-up captured attack characteristics, treatment use, health care use, and days lost without relying on long retrospective recall periods.
↳ Methods subsection “Data collection” and Table II
The paper reports message volume, response rate, observation time, treatment switching, attack counts, and treatment-period exposure. It also explicitly states that meaningful statistical comparison among treatment groups was impossible.
↳ Results subsection “Participant characteristics”; Table III; Discussion
Table I compares six earlier burden studies by population, method, and findings, while the Discussion addresses phase III evidence that differs from the observational severity results.
↳ Introduction, Table I, and Discussion
Limitations
Access to C1-INH prophylaxis required at least eight documented attacks per month, enriching prophylaxis groups for more severe baseline disease. No matching, adjustment, or sensitivity analysis addresses this confounding by indication.
↳ Methods subsection “Hereditary angioedema treatments”; Table III; Discussion
The article claims that modern prophylaxis “results in” reduced attack rates despite acknowledging that its observational sample could not support meaningful treatment-group comparison.
↳ Article summary box and Discussion
Productivity totals differ between the abstract and Results, and untreated attacks are reported as 186 in the main text but 103 in Figure E1. Quality-of-life measurements named in the objective are not reported.
↳ Abstract; Results subsections “Nontreated attacks” and “Loss of productivity”; Online Repository Figures E1–E2
The prospective SMS method and telephone follow-up provide useful low-recall descriptive information about attacks and treatment use. The central methodological problem is that prophylaxis access required very high baseline attack frequency, while the analysis did not control for confounding by indication. This makes the prominent claim that prophylaxis “results in” improved attack rates substantially stronger than the design permits. Table I and the Discussion provide meaningful context, but the conclusion does not consistently preserve the limitations acknowledged in the body.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Limited2.5
Confidence highThe prospective weekly SMS approach offers a modest methodological addition to earlier retrospective and web-based burden surveys. The burden findings are largely incremental, and the treatment comparisons do not resolve comparative-effectiveness uncertainty.
“This study demonstrates the feasibility of collecting real-time data using short message service.”
Weekly SMS ascertainment and attack follow-up are transparently described, but treatment access was conditioned on very high baseline attack frequency without adjustment for confounding by indication. The causal treatment conclusion therefore exceeds what the descriptive observational design can establish.
“it was impossible to perform a meaningful statistical comparison among treatment groups”
The methods, descriptive results, and limitations are generally followable. Reporting is reduced by prominent causal wording about prophylaxis that conflicts with the Discussion’s acknowledgment that meaningful treatment-group comparison was impossible.
“using modern prophylactic therapy for hereditary angioedema results in a reduction in attack rates”
Table I substantively distinguishes the study from earlier retrospective and web-based burden surveys, and the Discussion engages contrasting phase III evidence. However, the acknowledged limits on treatment comparison are contradicted by the concluding treatment-effect claim.
“Our study demonstrated that using modern prophylactic therapy results in an improvement in attack rates.”
Lower confidence on Contribution, Positioning — domain match limited.
Caveats4 of 4 checks
Several reported totals differ between the abstract, Results, and Online Repository, although the discrepancies do not overturn the descriptive burden finding. A stated quality-of-life objective is also not accompanied by reported quality-of-life results.
Ethics approval and informed consent are declared, and relevant financial relationships with HAE therapy manufacturers are disclosed. The absence of registration or data/code availability statements is not treated as a conduct concern for this observational study.
Flags: 2 declared / 5 total
10 of 11 checkable references verified
14 references in manuscript 3 are books, websites or datasets — counted, but not index-checkable
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
The SMS approach was implemented prospectively in a national patient cohort, supporting practical use as a monitoring method. Treatment and reimbursement recommendations remain preliminary because no credible comparative analysis was possible.
AI-generated, human-governed. Something look off? Contact us to request a review.